Dong Kim - 25 Mar 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
25 Mar 2022
Net transactions value
$0
Form type
4
Filing time
29 Mar 2022, 19:14:11 UTC
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Employee Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 25 Mar 2022 Ordinary Shares 30,000 $8.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One third of the shares underlying the stock option will vest on each of March 25, 2023, March 25, 2024 and March 25, 2025.